The Open UniversitySkip to content
 

miR-100-5p inhibition induces apoptosis in dormant prostate cancer cells and prevents the emergence of castration-resistant prostate cancer

Nabavi, Noushin; Saidy, Nur Ridzwan Nur; Venalainen, Erik; Haegert, Anne; Parolia, Abhijit; Xue, Hui; Wang, Yuwei; Wu, Rebecca; Dong, Xin; Collins, Colin; Crea, Francesco and Wang, Yuzhuo (2017). miR-100-5p inhibition induces apoptosis in dormant prostate cancer cells and prevents the emergence of castration-resistant prostate cancer. Scientific reports, 7(1), article no. 4079.

Full text available as:
[img]
Preview
PDF (Version of Record) - Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader
Download (5MB) | Preview
DOI (Digital Object Identifier) Link: https://doi.org/10.1038/s41598-017-03731-8
Google Scholar: Look up in Google Scholar

Abstract

Carcinoma of the prostate is the most common cancer in men. Treatment of aggressive prostate cancer involves a regiment of radical prostectomy, radiation therapy, chemotherapy and hormonal therapy. Despite significant improvements in the last decade, the treatment of prostate cancer remains unsatisfactory, because a significant fraction of prostate cancers develop resistance to multiple treatments and become incurable. This prompts an urgent need to investigate the molecular mechanisms underlying the evolution of therapy-induced resistance of prostate cancer either in the form of castration-resistant prostate cancer (CRPC) or transdifferentiated neuroendocrine prostate cancer (NEPC). By analyzing micro-RNA expression profiles in a set of patient-derived prostate cancer xenograft tumor lines, we identified miR-100-5p as one of the key molecular components in the initiation and evolution of androgen ablation therapy resistance in prostate cancer. In vitro results showed that miR-100-5p is required for hormone-independent survival and proliferation of prostate cancer cells post androgen ablation. In Silico target predictions revealed that miR-100-5p target genes are involved in key aspects of cancer progression, and are associated with clinical outcome. Our results suggest that mir-100-5p is a possible therapeutic target involved in prostate cancer progression and relapse post androgen ablation therapy.

Item Type: Journal Item
Copyright Holders: 2017 The Authors
ISSN: 2045-2322
Project Funding Details:
Funded Project NameProject IDFunding Body
Not SetNot SetCancer Research UK (CRUK)
Academic Unit/School: Faculty of Science, Technology, Engineering and Mathematics (STEM) > Life, Health and Chemical Sciences
Faculty of Science, Technology, Engineering and Mathematics (STEM)
Interdisciplinary Research Centre: Health and Wellbeing PRA (Priority Research Area)
Related URLs:
Item ID: 50028
Depositing User: Francesco Crea
Date Deposited: 07 Jul 2017 14:37
Last Modified: 16 Aug 2017 13:46
URI: http://oro.open.ac.uk/id/eprint/50028
Share this page:

Altmetrics

Download history for this item

These details should be considered as only a guide to the number of downloads performed manually. Algorithmic methods have been applied in an attempt to remove automated downloads from the displayed statistics but no guarantee can be made as to the accuracy of the figures.

Actions (login may be required)

Policies | Disclaimer

© The Open University   + 44 (0)870 333 4340   general-enquiries@open.ac.uk